Abstract: Novel indole and azaindole compounds of the following structure and their use as fructose-1,6-bisphosphatase inhibitors is described: ##STR1## and pharmaceutically acceptable prodrugs and salts thereof.
Type:
Grant
Filed:
March 6, 1998
Date of Patent:
April 25, 2000
Assignee:
Metabasis Therapeutics, Inc.
Inventors:
K. Raja Reddy, Gerard R. Scarlato, Qun Dang, Mark D. Erion, Srinivas Rao Kasibhatla, M. Rami Reddy
Abstract: Novel compounds which selectively inhibit adenosine kinase and methods of preparing adenosine kinase inhibitors are provided. Also provided are methods of treating various conditions which may be ameliorated by increased local concentrations of adenosine using adenosine kinase inhibitors.
Type:
Grant
Filed:
May 26, 1995
Date of Patent:
January 26, 1999
Assignee:
Metabasis Therapeutics, Inc.
Inventors:
Clinton E. Browne, Bheemarao G. Ugarkar, Kevin M. Mullane, Harry E. Gruber, David A. Bullough, Mark D. Erion, Angelo Castellino
Abstract: This invention relates to adenosine kinase inhibitors and to nucleoside analogs, specifically to water soluble, aryl substituted 4-amino pyrrolo?2,3-d! pyrimidine and pyrazolo?3,4-d! pyrimidine nucleoside analogs having activity as adenosine kinase inhibitors The invention also relates to the preparation and use of these adenosine kinase inhibitors in the treatment of cardiovascular, and cerebrovascular diseases, inflammation and other diseases which can be regulated by increasing the local concentration of adenosine.
Type:
Grant
Filed:
June 7, 1996
Date of Patent:
August 18, 1998
Assignee:
Metabasis Therapeutics, Inc.
Inventors:
Bheemarao G. Ugarkar, Mark D. Erion, Jorge E. Gomez Galeno
Abstract: This invention relates to adenosine kinase inhibitors and to nucleoside analogs, C-4' modified pyrrolo?2,3-d!pyrimidine and pyrazolo?3,4-d!pyrimidine nucleoside analogs having activity as adenosine kinase inhibitors. The invention relates to nucleoside analogs of this kind, having zero substitutions or two substitutions at the C-4' position of the furanose (sugar) moiety. The invention also relates to the preparation and use of these adenosine kinase inhibitors in the treatment of cardiovascular, and cerebrovascular diseases, inflammation and other diseases which can be regulated by increasing the local concentration of adenosine.
Type:
Grant
Filed:
June 7, 1996
Date of Patent:
June 9, 1998
Assignee:
Metabasis Therapeutics, Inc.
Inventors:
Serge H. Boyer, Bheemarao G. Ugarkar, Mark D. Erion
Abstract: This invention relates to adenosine kinase inhibitors and to nucleoside analogs, specifically to orally active, substituted 5-aryl pyrrolo?2,3-d! pyrimidine and 3-aryl pyrazolo?3,4-d! pyrimidine nucleoside analogs having activity as adenosine kinase inhibitors. The invention also relates to the preparation and use of these and other adenosine kinase inhibitors in the treatment of cardiovascular and cerebrovascular diseases, inflammation and other diseases which can be regulated by increasing the local concentration of adenosine.
Type:
Grant
Filed:
June 7, 1996
Date of Patent:
June 9, 1998
Assignee:
Metabasis Therapeutics, Inc.
Inventors:
Bheemarao G. Ugarkar, Mark D. Erion, Jorge E. Gomez Galeno, Angelo J. Castellino, Clinton E. Browne